OC
ACAD icon

Oppenheimer & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

Oppenheimer & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,001
Closed -$412K – 1376
2013
Q3 		$412K Hold
15,001
– – 0.01% 836
2013
Q2 		$272K Buy
+15,001
New +$207K 0.01% 968

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oppenheimer & Co's ACAD Position: Q4 2013 in Review

Oppenheimer & Co sold out of Acadia Pharmaceuticals (ACAD) in Q4 2013, closing a stake of 15,001 shares — an estimated $412K sold.

Oppenheimer & Co first reported a position in ACAD in Q2 2013 and held it in 2 quarters. The position peaked at $412K in Q3 2013. 155 funds tracked by Wall St. Rank hold ACAD as of Q4 2013.

  • Oppenheimer & Co reported no remaining Acadia Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Oppenheimer & Co sold 15,001 Acadia Pharmaceuticals shares in Q4 2013, an estimated $412K.
  • Oppenheimer & Co first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Oppenheimer & Co's Acadia Pharmaceuticals position peaked at $412K in Q3 2013.
  • 155 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2013.

Based on Oppenheimer & Co's 13F filing for Q4 2013, filed 12 Feb 2014.